Education
About Us
Working with TipRanks
Follow Us
Telix Pharmaceuticals Ltd. (AU:TLX)
ASX:TLX
RESEARCH TOOLSreports
Earnings Data
Report Date
Aug 21, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.29Last Year’s EPS
0.09Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 20, 2025
|% Change Since: 3.24%
|Next Earnings Date:Aug 21, 2025
Earnings Call Sentiment|Positive
The earnings call reflects strong financial performance and strategic growth through acquisitions and R&D investments. Despite potential regulatory delays and market uncertainties, Telix is well-positioned for significant expansion with an innovative product pipeline.Company Guidance
In the Telix Pharmaceuticals Limited FY 2024 Results Call, the company provided a positive outlook for the upcoming year, 2025, with guidance well exceeding one billion dollars in revenue. This projection does not yet account for product launches in regions pending regulatory approvals. The company has reported a strong performance in 2024, with a 56% revenue improvement, a 70% increase in adjusted EBITDA to $99 million, and an impressive 860% rise in profit after tax. The cash position at year-end was solid at $710 million, bolstered by a convertible bond placement. The company's growth strategy focuses on expanding its product pipeline, launching new products, and enhancing its global manufacturing and distribution infrastructure. As it transitions into a therapeutics company, Telix plans to significantly increase its R&D investment by 20% to 25% over 2024 numbers to support this growth.Revenue and Growth Metrics
Telix achieved a 56% revenue increase, adjusted EBITDA improved by 70% to $99 million, operating cash inflow improved by 80%, and profit after tax surged 860%.
Illuccix Sales Performance
Illuccix drove revenue growth for the 10th consecutive quarter with over $500 million in U.S. sales for 2024, reflecting strong market momentum.
Acquisitions and R&D Investment
Significant acquisitions like ARTMS and IsoTherapeutics, along with a $195 million investment in R&D, are supporting strategic growth and pipeline expansion.
Global Expansion Strategy
Plans to launch three new products in the U.S. and expand precision medicine portfolio into Europe and Asia-Pacific regions.
Innovative Product Pipeline
Telix is advancing late-stage assets for prostate, kidney, and brain cancer, with several alpha therapies entering first-in-human trials in 2025.
---
AU:TLX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AU:TLX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 20, 2025 | AU$26.82 | AU$26.46 | -1.34% |
| Aug 22, 2024 | AU$19.97 | AU$19.78 | -0.95% |
| Feb 22, 2024 | AU$11.00 | AU$10.97 | -0.27% |
| Aug 23, 2023 | AU$9.87 | AU$9.79 | -0.81% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Telix Pharmaceuticals Ltd. (AU:TLX) report earnings?
Telix Pharmaceuticals Ltd. (AU:TLX) is schdueled to report earning on Aug 21, 2025, TBA Not Confirmed.
What is Telix Pharmaceuticals Ltd. (AU:TLX) earnings time?
Telix Pharmaceuticals Ltd. (AU:TLX) earnings time is at Aug 21, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Telix Pharmaceuticals Ltd. stock?
The P/E ratio of Telix Pharmaceuticals Ltd. is N/A.
What is AU:TLX EPS forecast?
AU:TLX EPS forecast for the fiscal quarter 2025 (Q2) is 0.29.
---